<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1: Clinically Significant Drug Interactions with Naproxen</caption>
<col></col>
<col></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Drugs That Interfere with Hemostasis </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <list listtype="unordered" stylecode="Disk">
<item>Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of naproxen and anticoagulants has an increased risk of serious bleeding compared to the use of either drug alone.</item>
<item>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. </item>
</list>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Monitor patients with concomitant use of naproxen tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding <content stylecode="italics">(see WARNINGS; Hematologic Toxicity)</content>. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Aspirin </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone <content stylecode="italics">(see WARNINGS; Gastrointestinal Bleeding, Ulceration and Perforation)</content>. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant use of naproxen tablets and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (<content stylecode="italics">see WARNINGS; Hematologic Toxicity</content>). Naproxen tablets are not a substitute for low dose aspirin for cardiovascular protection. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <list listtype="unordered" stylecode="Disk">
<item>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</item>
<item>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. </item>
</list>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <list listtype="unordered" stylecode="Disk">
<item>During concomitant use of naproxen tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</item>
<item>During concomitant use of naproxen tablets and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function <content stylecode="italics">(see WARNINGS; Renal Toxicity and Hyperkalemia)</content>. When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter. </item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Diuretics </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>During concomitant use of naproxen tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects <content stylecode="italics">(see WARNINGS; Renal Toxicity and Hyperkalemia)</content>. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Digoxin </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>During concomitant use of naproxen tablets and digoxin, monitor serum digoxin levels. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Lithium </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>During concomitant use of naproxen tablets and lithium, monitor patients for signs of lithium toxicity. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Methotrexate</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>During concomitant use of naproxen tablets and methotrexate, monitor patients for methotrexate toxicity. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Cyclosporine </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant use of naproxen tablets and cyclosporine may increase cyclosporine’s nephrotoxicity. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>During concomitant use of naproxen tablets and cyclosporine, monitor patients for signs of worsening renal function. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">NSAIDs and Salicylates </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant use of naproxen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy <content stylecode="italics">(see WARNINGS; Gastrointestinal Bleeding, Ulceration and Perforation)</content>. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Pemetrexed </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant use of naproxen tablets and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity <content stylecode="italics">(see the pemetrexed prescribing information).</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>During concomitant use of naproxen tablets and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Antacids and Sucralfate </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant administration of some antacids (magnesium oxide or aluminum hydroxide) and sucralfate can delay the absorption of naproxen. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant administration of antacids such as magnesium oxide or aluminum hydroxide, and sucralfate with naproxen tablets are not recommended. Due to the gastric pH elevating effects of H2-blockers, sucralfate and intensive antacid therapy, concomitant administration of naproxen tablets are not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Cholestyramine </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant administration of cholestyramine can delay the absorption of naproxen. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Concomitant administration of cholestyramine with naproxen tablets are not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Probenecid </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Patients simultaneously receiving naproxen tablets and probenecid should be observed for adjustment of dose if required. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="bold">Other albumin-bound drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Naproxen is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as coumarin-type anticoagulants, sulphonylureas, hydantoins, other NSAIDs, and aspirin. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>Patients simultaneously receiving naproxen tablets and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required. </paragraph>
</td>
</tr>
</tbody>
</table>